1584713-87-0 Usage
General Description
BMS-983970, also known as Galunisertib, is a small molecule inhibitor of the TGF-β receptor kinase. It has shown promising results in preclinical studies for the treatment of various types of cancer, such as pancreatic, colorectal, and glioblastoma. BMS-983970 works by blocking the activity of the TGF-β pathway, which is known to promote tumor growth, invasion, and metastasis. In clinical trials, BMS-983970 has demonstrated potential therapeutic efficacy as a single agent or in combination with other cancer treatments. It is currently being investigated for its potential in the treatment of solid tumors and fibrosis. However, further research is needed to determine its safety and effectiveness for the treatment of cancer and other diseases.
Check Digit Verification of cas no
The CAS Registry Mumber 1584713-87-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,5,8,4,7,1 and 3 respectively; the second part has 2 digits, 8 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1584713-87:
(9*1)+(8*5)+(7*8)+(6*4)+(5*7)+(4*1)+(3*3)+(2*8)+(1*7)=200
200 % 10 = 0
So 1584713-87-0 is a valid CAS Registry Number.
1584713-87-0Relevant articles and documents
ALKYL, FLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS
-
, (2014/04/04)
Disclosed are compounds of Formula (I) and/or salts thereof: (I) wherein: R1 is CH2CH2CF3; R2 is CH2(cyclopropyl), CH(CH3)(cyclopropyl), or CH2CH2CH3/
